Description
PF-08634404 is a new medication currently being studied in a Phase 3 clinical trial (NCT07222800) for people with metastatic colorectal cancer (CRC) that has spread or returned after previous treatments. This trial, sponsored by Pfizer, is comparing PF-08634404 combined with standard chemotherapy to bevacizumab combined with standard chemotherapy. The goal is to see if PF-08634404 can help people with advanced CRC. Participants in the trial must be 18 years or older and in good enough health to receive treatment. The treatment involves intravenous (IV) infusions given in cycles at a clinical site. Participants will be closely monitored by medical staff during and after treatment. The study is expected to last for each participant for about 33 months, including treatment and follow-up.
Mechanism of Action
PF-08634404 is a new investigational medication. The specific way it works (its mechanism of action) is being studied in clinical trials. It is being tested in combination with chemotherapy to see if it can improve outcomes for people with metastatic colorectal cancer.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.